Subject matter of the present invention is a lyophilized kit formulation for the preparation of radiometal labeled chelate-functionalized GRP receptor targeting conjugates comprising
a chelate-functionalized GRP receptor targeting conjugate comprising
i. a chelating moiety
ii. at least one targeting moiety, wherein said targeting moiety is a GRP receptor (GRPr) targeting peptide, and
iii. optionally, at least one linker, connecting the chelating moiety with the GRP receptor (GRPr) targeting moiety, and
at least one GRP receptor (GRPr) targeting moiety,
at least one non-reducing sugar selected from the group comprising trehalose and sucrose, and
at least one radio stabilizer, selected from the group comprising ascorbic acid, ascorbic acid salts, gentisic acid, gentisic acid salts, or mixtures thereof.
Subject matter of the present invention is a lyophilized kit formulation for the preparation of radiometal labeled chelate-functionalized GRP receptor targeting conjugates comprising • a chelate-functionalized GRP receptor targeting conjugate comprising i. a chelating moiety ii. at least one targeting moiety, wherein said targeting moiety is a GRP receptor (GRPr) targeting peptide, and iii. optionally, at least one linker, connecting the chelating moiety with the GRP receptor (GRPr) targeting moiety, and • at least one GRP receptor (GRPr) targeting moiety, • at least one non-reducing sugar selected from the group comprising trehalose and sucrose, and • at least one radio stabilizer, selected from the group comprising ascorbic acid, ascorbic acid salts, gentisic acid, gentisic acid salts, or mixtures thereof.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Diagnostic preparations for clinical laboratory use; Diagnostic preparations for medical laboratory use; Diagnostic reagents for medical diagnostic use; Diagnostic preparations for medical purposes, namely radioactive tracers for use in diagnostic imaging to identify cardiovascular diseases.
The present application relates to a diagnostic composition comprising:
a. a compound of Formula I,
The present application relates to a diagnostic composition comprising:
a. a compound of Formula I,
b. ethanol,
c. water, and
d. a hydroxycarboxylic acid, a salt of a hydroxycarboxylic acid or a mixture thereof.
The present application relates to a diagnostic composition comprising:
a. a compound of Formula I,
b. ethanol,
c. water, and
d. a hydroxycarboxylic acid, a salt of a hydroxycarboxylic acid or a mixture thereof.
The diagnostic composition can be used in the selective detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's disease (AD) and other tauopathies, for example, using Positron Emission Tomography (PET). The present invention also relates to a method of preparing the claimed diagnostic composition.
The present invention relates to novel compounds of the formula (II) and formula (III)
that can be employed in the selective Tau detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's disease and other tauopathies using Positron Emission Tomography (PET) Imaging.
The present invention relates to novel compounds of the formula (II)
that can be employed in the selective Tau detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's disease and other tauopathies using Positron Emission Tomography (PET) Imaging.
The present invention relates to novel compounds of the formula (I)
that can be employed in the selective Tau detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's disease and other tauopathies using Positron Emission Tomography (PET) Imaging.
18F, methods of preparing such a compound, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for diagnostic imaging by positron emission tomography (PET).
C07D 291/08 - Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
C07B 59/00 - Introduction of isotopes of elements into organic compounds
C07C 211/42 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes
C07B 59/00 - Introduction of isotopes of elements into organic compounds
C07C 213/08 - Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
13.
Compounds for binding to the platelet specific glycoprotein IIb/IIIa and their use for imaging of thrombi
The present invention relates to novel fluorine containing compounds, methods for their preparation, the intermediates of the synthesis, their use as diagnostic agents, especially for imaging of thrombi. The invention relates to positron emission tomography (PET) agents and associated precursor reagents, and methods for producing such radiolaveled agents for imaging of thrombi in a mammalian body. More particularly, the invention relates to small nonpeptide, high-affinity, specific-binding glycoprotein IIb/IIIa antagonists for imaging of thrombi.
C07D 211/60 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
14.
Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors
18F, methods of preparing such a compound, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for diagnostic imaging by positron emission tomography (PET).
C07D 291/08 - Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
C07B 59/00 - Introduction of isotopes of elements into organic compounds
C07C 211/42 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
The present invention relates to novel fluorine containing compounds, methods for their preparation, the intermediates of the synthesis, their use as diagnostic agents, especially for imaging of thrombi. The invention relates to positron emission tomography (PET) agents and associated precursor reagents, and methods for producing such radiolaveled agents for imaging of thrombi in a mammalian body. More particularly, the invention relates to small nonpeptide, high-affinity, specific-binding glycoprotein 11b/IIIa antagonists for imaging of thrombi.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
The invention is directed to formulations of lipophilic Amyloid beta ligand stilbene and more particularly to formulations which are capable to be administered parenterally e.g. intravenously, wherein the lipophilic Amyloid beta ligand stilbene is a fluorinated stilbene. Further, the invention is directed to a method for sterile filtration of formulations suitable for PET imaging of mammals pursuant to the invention.
C07C 211/29 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
C07D 213/64 - One oxygen atom attached in position 2 or 6
C07C 213/08 - Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Diagnostic agents, preparations and substances for medical purposes; diagnostic scanning agents for medical use, namely, diagnostic scanning agents for in vivo use; radiopharmaceutical diagnostic preparations for medical use; radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative amyloid diseases
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Diagnostic agents, preparations and substances for medical purposes; diagnostic scanning agents for medical use, namely, diagnostic scanning agents for in vivo use; radiopharmaceutical diagnostic preparations for medical use; radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative amyloid diseases.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Diagnostic scanning agents for medical use, namely, diagnostic scanning agents for in vivo use; radioactive pharmaceutical preparations for in vivo diagnostic or therapeutic use radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative amyloid diseases.
22.
Usage of low to medium-pressure liquid chromatography for the purification of radiotracers
The invention relates to a process for the production of radiotracers. In particular, this invention relates the isolation of radiotracers with containers filled with a stationary phase.
18F, methods of preparing such a compound, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for diagnostic imaging by positron emission tomography (PET).
18F, methods of making such compounds and use of such compounds for diagnostic imaging. Such labeled compounds are characterized by Formula II, wherein the substituents G, Q, L, Y and U have the meaning as defined in the specification and claims.
Subject matter of the present invention is a lyophilized kit formulation for the preparation of radiometal labeled chelate-functionalized GRP receptor targeting conjugates comprising ? a chelate-functionalized GRP receptor targeting conjugate comprising i. a chelating moiety ii. at least one targeting moiety, wherein said targeting moiety is a GRP receptor (GRPr) targeting peptide, and iii. optionally, at least one linker, connecting the chelating moiety with the GRP receptor (GRPr) targeting moiety, and ? at least one GRP receptor (GRPr) targeting moiety, ? at least one non-reducing sugar selected from the group comprising trehalose and sucrose, and ? at least one radio stabilizer, selected from the group comprising ascorbic acid, ascorbic acid salts, gentisic acid, gentisic acid salts, or mixtures thereof.
